Press Releases Santhera Pharmaceuticals Holding AG OTC Markets

Equities

SPHDF

CH1276028821

Delayed OTC Markets Other stock markets 10:53:09 22/02/2024 pm IST			5-day change	1st Jan Change
11.7 ^USD	+4.00%		-.--%	-.--%

19/06	Transcript : Santhera Pharmaceuticals Holding AG - Special Call
18/06	Santhera Secures CHF69 Million Financing for Bond Repayment, Cash Runway Extension	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Santhera’s Shareholders Approve all Board Proposals at Today’s Annual General Meeting	18/06	AQ
Santhera Secures up to CHF 69 million in Royalty and Debt Financing to Fund Operations to Cash Flow Break-Even	18/06	AQ
Santhera Announces Launch of Early Access Program in China for AGAMREE® by its Partner Sperogenix	10/06	AQ
Santhera Publishes Agenda for its Annual General Meeting	28/05	AQ
Santhera Publishes Annual Report 2023	28/05	AQ
Santhera Announces Preliminary Unaudited 2023 Annual Results and Provides Corporate Update Ahead of Full Report Publication in May	25/04	AQ
Santhera Announces NDA for Vamorolone in Duchenne Muscular Dystrophy Accepted and Granted Priority Review by China’s NMPA	27/03	AQ
Santhera’s Partner Catalyst Pharmaceuticals Launches AGAMREE® (Vamorolone) in the United States	14/03	AQ
Santhera Announces Publication of Efficacy, Safety and Tolerability Data with Vamorolone (AGAMREE®) in Patients with Duchenne Muscular Dystrophy in Neurology	14/02	AQ
Santhera Launches AGAMREE® (Vamorolone) in Germany as First Market for the Treatment of Duchenne Muscular Dystrophy	15/01	AQ
Santhera Receives Approval for AGAMREE® (Vamorolone) as a Treatment for Duchenne Muscular Dystrophy in the United Kingdom	12/01	AQ
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy	18/12	AQ
Santhera Appoints Executive Committee Members as it Transitions into Commercial Stage	07/12	AQ
Catalyst Pharmaceuticals Reports FDA Approval of AGAMREE for Duchenne Muscular Dystrophy Granted to Santhera Pharmaceuticals	27/23/27	AQ
Santhera Receives U.S. FDA Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy	27/23/27	AQ
Santhera Receives Positive CHMP Opinion Recommending Approval of AGAMREE® (vamorolone) for the Treatment of Duchenne Muscular Dystrophy	13/23/13	AQ
Santhera Announces Half-Year 2023 Financial Results and Provides Corporate Update	07/23/07	AQ
Santhera Completes Divestment of Raxone®/Idebenone Business to Chiesi Group	31/23/31	AQ
Santhera Announces Closing of Exclusive North America License Agreement with Catalyst Pharmaceuticals for Vamorolone	19/23/19	AQ
Santhera Publishes Timeline of the Reverse Share Split	29/23/29	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Santhera Pharmaceuticals Holding AG OTC Markets

Equities

SPHDF

CH1276028821

Press Releases

Filters